{"protocolSection": {"identificationModule": {"nctId": "NCT02053246", "orgStudyIdInfo": {"id": "IRB201501144 -N"}, "secondaryIdInfos": [{"id": "K23GM112014", "type": "NIH", "link": "https://reporter.nih.gov/quickSearch/K23GM112014"}], "organization": {"fullName": "University of Florida", "class": "OTHER"}, "briefTitle": "Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure", "officialTitle": "Improving Treatment Personalization of Pulmonary Hypertension Associated With Diastolic Heart Failure"}, "statusModule": {"statusVerifiedDate": "2022-01", "overallStatus": "TERMINATED", "whyStopped": "Study funding ended before recruitment completed.", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-01", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2021-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2021-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-01-24", "studyFirstSubmitQcDate": "2014-01-30", "studyFirstPostDateStruct": {"date": "2014-02-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2022-01-19", "resultsFirstSubmitQcDate": "2022-01-19", "resultsFirstPostDateStruct": {"date": "2022-02-10", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2022-01-19", "lastUpdatePostDateStruct": {"date": "2022-02-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "University of Florida", "class": "OTHER"}, "collaborators": [{"name": "National Institute of General Medical Sciences (NIGMS)", "class": "NIH"}]}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "Heart failure with preserved ejection fraction (HFpEF), is one of the leading causes of pulmonary hypertension (PH). Despite the severity of this disease, no established treatments exist for this class of PH. Nebivolol is a drug used in high blood pressure and heart failure, but not used in patients with PH. Due to some additional properties it possesses, the investigators believe nebivolol will improve disease severity in patients with PH associated with HFpEF. The hypothesis of this research study is that nebivolol improves PH severity in patients with HFpEF, as measured by hemodynamic and clinical parameters.", "detailedDescription": "This research study will be a prospective, open-label 18-week clinical study of nebivolol in patients with PH associated with HFpEF. Patients will be identified in clinic based on echocardiogram (TTE) and right heart catheterization (RHC) results (both part of standard clinical care) indicating PH and HFpEF."}, "conditionsModule": {"conditions": ["Pulmonary Hypertension", "Diastolic Heart Failure", "Heart Failure With Preserved Ejection Fraction"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE4"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 11, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Nebivolol", "type": "EXPERIMENTAL", "description": "Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.", "interventionNames": ["Drug: Nebivolol"]}], "interventions": [{"type": "DRUG", "name": "Nebivolol", "description": "Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.", "armGroupLabels": ["Nebivolol"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Changes in Pulmonary Vascular Pressure", "description": "Difference between baseline and 18 week mean pulmonary artery pressure and pulmonary artery wedge pressure", "timeFrame": "baseline - 18 weeks"}], "secondaryOutcomes": [{"measure": "Changes in 6-minute Walk Distance", "description": "Difference in 6-minute walk distance between baseline and 18 weeks.", "timeFrame": "baseline - 18 weeks"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Adults (\u2265 18 years of age) with World Health Organization Group 2 Pulmonary Hypertension (Mean pulmonary artery pressure \u2265 25 mmHg and pulmonary capillary wedge pressure \u2265 15 mmHg)\n* New York Heart Association class II-IV symptoms\n* Left ventricular ejection fraction (LVEF) \u2265 45%\n\nExclusion Criteria:\n\n* Other causes of heart failure other than diastolic dysfunction, such as restrictive cardiomyopathy or infiltrative cardiomyopathy\n* Women who are pregnant or nursing\n* Liver cirrhosis,\n* Primary valvular disease\n* Acute coronary syndrome\n* Causes of PH other than that of heart failure, such as: chronic thromboembolic PH, sickle-cell disease, or sarcoidosis\n* Severe bradycardia or greater than 1st degree heart block\n* Decompensated heart failure\n* Current use of a third generation beta-blocker (nebivolol, carvedilol, or labetalol) or high dose of any beta-blockers (greater than 100 mg daily of metoprolol, or equivalent)", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Julio Duarte, PharmD, PhD", "affiliation": "University of Florida", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "University of Florida", "city": "Gainesville", "state": "Florida", "zip": "32611", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}]}, "ipdSharingStatementModule": {"ipdSharing": "UNDECIDED"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Nebivolol", "description": "Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.\n\nNebivolol: Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "11"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Nebivolol", "description": "Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.\n\nNebivolol: Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "65.8", "spread": "9.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "9"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "2"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}]}], "categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "10"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "4"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "6"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "1"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "11"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}]}]}]}, {"title": "Weight", "populationDescription": "2 patients withdrew before measurement", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "93.0", "spread": "29.8"}]}]}]}, {"title": "Height", "populationDescription": "2 patients withdrew before measurement", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "164.6", "spread": "9.4"}]}]}]}, {"title": "Systolic Blood Pressure", "populationDescription": "2 patients withdrew before measurement", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "130.1", "spread": "16.0"}]}]}]}, {"title": "Diastolic Blood Pressure", "populationDescription": "2 patients withdrew before measurement", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "68.0", "spread": "12.7"}]}]}]}, {"title": "Mean Pulmonary Artery Pressure", "populationDescription": "2 patients withdrew before measurement", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "35.2", "spread": "7.2"}]}]}]}, {"title": "Pulmonary Artery Wedge Pressure", "populationDescription": "2 patients withdrew before measurement", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmHg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "19.6", "spread": "3.7"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Changes in Pulmonary Vascular Pressure", "description": "Difference between baseline and 18 week mean pulmonary artery pressure and pulmonary artery wedge pressure", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "baseline - 18 weeks", "groups": [{"id": "OG000", "title": "Nebivolol", "description": "Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.\n\nNebivolol: Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "classes": [{"title": "Mean Pulmonary Artery Pressure Change", "categories": [{"measurements": [{"groupId": "OG000", "value": "0.43", "spread": "6.32"}]}]}, {"title": "Pulmonary Artery Wedge Pressure Change", "categories": [{"measurements": [{"groupId": "OG000", "value": "1.0", "spread": "7.0"}]}]}]}, {"type": "SECONDARY", "title": "Changes in 6-minute Walk Distance", "description": "Difference in 6-minute walk distance between baseline and 18 weeks.", "populationDescription": "Only patients who were able to complete walk tests at baseline and final study visits.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "feet", "timeFrame": "baseline - 18 weeks", "groups": [{"id": "OG000", "title": "Nebivolol", "description": "Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.\n\nNebivolol: Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "4"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-44.0", "spread": "299.8"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Data were collected from enrollment until completion of final study visit at week 18.", "eventGroups": [{"id": "EG000", "title": "Nebivolol", "description": "Participants will be started at 2.5 mg of nebivolol by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.\n\nNebivolol: Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.", "deathsNumAffected": 0, "deathsNumAtRisk": 9, "seriousNumAffected": 0, "seriousNumAtRisk": 9, "otherNumAffected": 2, "otherNumAtRisk": 9}], "otherEvents": [{"term": "Dizziness", "organSystem": "General disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}, {"term": "Fluid retention", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 9}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Trial was stopped prior to completion because funding ended."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Dr. Julio Duarte", "organization": "University of Florida", "email": "juliod@cop.ufl.edu", "phone": "352-273-8132"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2018-10-08", "uploadDate": "2022-01-19T15:53", "filename": "Prot_SAP_000.pdf", "size": 286766}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2019-03-06", "uploadDate": "2022-01-19T15:56", "filename": "ICF_001.pdf", "size": 202440}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006976", "term": "Hypertension, Pulmonary"}, {"id": "D000006973", "term": "Hypertension"}, {"id": "D000006333", "term": "Heart Failure"}, {"id": "D000054144", "term": "Heart Failure, Diastolic"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M10027", "name": "Hypertension, Pulmonary", "asFound": "Pulmonary Hypertension", "relevance": "HIGH"}, {"id": "M27580", "name": "Heart Failure, Diastolic", "asFound": "Diastolic Heart Failure", "relevance": "HIGH"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068577", "term": "Nebivolol"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000014665", "term": "Vasodilator Agents"}, {"id": "D000058665", "term": "Adrenergic beta-1 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M276", "name": "Nebivolol", "asFound": "2.4", "relevance": "HIGH"}, {"id": "M3671", "name": "Adrenergic beta-Antagonists", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M17412", "name": "Vasodilator Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "VaDiAg", "name": "Vasodilator Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}